Clinical trials: Pancreatic Neuroendocine Neoplasms (pNETs)
Pancreatic Neuroendocine Neoplasms (pNETs)
Risk Factors, Prognosis, Clinicopathological and Metabolic Characteristics of EO- vs LO-PanNETs
The aim of this observational multicenter retrospective cohort study is to evaluate the differences in risk factors, prognosis, clinicopathological and metabolic characteristics between early-onset pancreatic neuroendocrine…
- Trial name
- NCT07136701
- Where
- 2 sites in China
- Volunteers
- 600 people
- Sponsor
- Qilu Hospital of Shandong University
Neoplasms, Breast Neoplasms
Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
Dose escalation part: to determine the highest dose of alpelisib administered on a daily basis when given in combination with daily everolimus or in combination with daily everolimus and exemestane.
- Conditions
- Neoplasms, Breast Neoplasms, Kidney Neoplasms, Pancreatic Neuroendocine Neoplasms (pNETs)
- Trial name
- NCT02077933
- Testing
- alpelisib, everolimus, exemestane
- Where
- 22 sites in United States, France and 7 more
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Cancer, Pancreatitis
Validation of Joint-AI in Diagnosing Pancreatic Solid Lesions
This clinical trial aims to learn if a multimodal artificial intelligence (AI) model can enhance the diagnosis of pancreatic solid lesions. The main questions it aims to answer are: 1.
- Conditions
- Pancreatic Cancer, Pancreatitis, Pancreatic Neuroendocine Neoplasms (pNETs), Autoimmune Pancreatitis
- Trial name
- NCT06753318
- Testing
- The assistance of the Joint-AI model, The assistance of the interpretable Joint-AI model
- Where
- China
- Volunteers
- 716 people
- Sponsor
- Huazhong University of Science and Technology